Abstract
Introduction
Various cutaneous lesions observed in hematologic malignancies include specific cutaneous diseases resulting from infiltration of the skin by the malignant cells. Non specific cutaneous lesions resulting from infection or hemorrhage resulting from the bone marrow dysfuction induced by the malignant process or chemotherapy. There are some characteristic diseases such as pyoderma gangrinosum and sweet syndrome may be associated with hematologic malignancies. 1 Non-specific skin lesions are more common in patients with Hodgkins diseases. 2 Generalized severe pruritus may precede other finding of Hodgking disease by many months or may occur in patients with a known diagnosis. 3 An evaluation for underlying lymphoma should be considered in patient with severe itching. 4 The cutaneous manifestations of leukemias are divided into non-specific benign lesions and specific malignant lesions. Specific lesions (leukemia cutis) are localized or disseminated infiltrations of the skin by malignant leukemic cells which may involve all layers of the skin. The clinical appearance of leukemia cutis is variable and may range from papules and nodules to a generalized cutaneous eruption. 5 The histopathologic examination of the skin lesion is essential for diagnosis of leukemia cutis. Specific skin lesions are usually observed in patients with an aggressive clinical course and are associated with a poor prognosis. 6 However, an overall survival of patients with specific skin lesions of chronic lymphocytic leukemia is significantly better, as compared with other types of leukemia. Rarely, skin lesions containing leukemic cells may be present before evidence of leukemia in the peripheral blood and bone marrow (aleukemic leukaemia cutis). Specific cutaneous involvement has been reported in 10% to 50% of patients with acute myelogenous leukemia and in about 2% ofpatients with chronic myelogenous leukemia (CML). 1, 3, 6 Clinical and histopathologic features are variable. [7] [8] [9] [10] [11] [12] This study was carried out to demonstrated cutaneous findings of various hematological malignencies that may help in planning subsequent management of these patients, especially in cases where skin lesions precede the onset of leukemia.
Methods
This cross sectional observational study was carried out in the Hematology department of Bangabandhu Sheikh Mujib Medical University from January 2012 to January 2013. Total 127 consecutive patients who were already diagnosed as haematological malignancies & hospitalized were evaluated at the period of one year. All age groups & those who were willing to give informed written consent were included in this study. Study protocol was approved by the ethical committee of BSMMU.
Results
Most of the patients 51(40.15%) of Hematologic malignancies were between 41-60 years of age group. (Table-I ) We found total 8(6.29%) patients suffering from malignant infiltration. Among them, out of 11 CML patients 3(2.36%) had malignant infiltration of the skin.
One study done at Turkey they have got malignant infiltration in 6(22.27%) patients out of 22 CML patients. 20 This study is correlated with our study.
Mucosal hemorrhages, ulcerative gingivitis, infectious gingivitis and odontalgia may be observed. 21, 22 Pallor, spontaneous hemorrhage, petechiae and ulceration have been described to occur more frequently in acute than chronic leukemia. 22 In our study population 17 patients were suffering from hemorrhagic lesions and among them 9 patients had ALL. Petechiae and ecchymosis were observed secondary to thrombocytopenia were grouped as hemorrhagic findings.
Gingival hyperplasia is secondary to infiltration of the gingival tissue with leukemia cells and is well described in the literature. In the most extensive review of the topic, gingival hyperplasia was observed in AML with a frequency of 3% to 5% among 1,076 patients receiving anti-leukemia chemotherapy at a referral centre.20 Gingival hyperplasia is most commonly seen with AML patients. We found gingival hyperplasia in 3(2.36%) patients out of 31 AML patients. Another study by Yalcin AD et al showed gingival hyperplasia in 4 patients out of 21 AML patients. 20 This study nearly correlated with our study.
Cutaneous involvement in malignant lymphomas may be primary or secondary. Malignant lymphomas may occur de novo in the skin or after spread from internal organs. We found fixed drug reaction in 5(3.93%) patients. Out of them one patient was of hodgkin lymphoma triggered by vincristine another two found in CML patient, one in hodgkin lymphoma and one in multiple myeloma patient.
Out of 127 patients we did not get any skin infestation in 43(35.85%) patients. We have got skin manifestations in 75 patients. It is the commonest (66.75%) and about two third of our study population.
About two third of our patients (66.75%) had skin lesions independent from malignancy types. No statistical difference was found between different type of malignant disorders according to lesions. Malignant infiltrative lesions & hemorrhagic findings, both were predominant in leukemia. Infections were predominant in both leukemia & lymphoma. Large scale study is needed for further evaluation.
